ライフサイエンスコーパス: A(1) receptor agonist

1 tric oxide synthase inhibitors and adenosine A1 receptor agonists.

2 However, incubation with the adenosine A(1) receptor agonist 2-chlorocyclopentyladenosine induc

3 te receptor antagonist MK-801; the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC

4 The A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (CC

5 The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC

6 However, the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine and

7 stantial increase in CoRCF and CoVC, but the A1 receptor agonist 2-chloro-N6-cyclopentyladenosine had

8 ) receptor agonist baclofen or the adenosine A1 receptor agonist 2-chloroadenosine, short-term synapt

9 The selective adenosine A1 receptor agonists 2-chloro-N6-cyclopentyladenosine (C

10 ould be demonstrated only with the selective A1-receptor agonist 2-chloro-N6-cyclopentyladenosine and

11 ischemic preconditioning, but the adenosine A(1) receptor agonist, 2-chloro-N(6)-cyclopentyladenosin

12 cked by exogenous adenosine or the selective A1 receptor agonist, 2-chloro-N6-cyclopentyl adenosine.

13 5.5% with SfA; P<0.001), CCPA (the adenosine A1-receptor agonist, 200 nmol/L) (24.9+/-4.5% versus 54.

14 These data are consistent with adenosine A1 receptor agonist actions on REM sleep mediated throug

15 the antiinflammatory effects of intrathecal A1 receptor agonists and AP-5 were reversed by an adenos

16 ine, N(6)-cyclopentyladenosine (an adenosine A(1) receptor agonist), and 2-[p-(2-carboxyethyl)]phenyl

17 A(1) receptor agonists, but not other purinoceptor-type

18 After diclofenac, the A(1) receptor agonist CCPA evoked no vasodilatation: we

19 or sodium nitroprusside (SNP), the adenosine A1 receptor agonist CCPA (2-chloro-N6-cyclopentyladenosi

20 receptor agonist APEC, but not the adenosine A1 receptor agonist CHA, attenuated c-Fos induction in c

21 lices containing the PnOc incubated with the A1 receptor agonist, cyclohexaladenosine (10(-8) M).

22 rats were treated IT with the selective Ado A1 receptor agonist cyclohexyladenosine (CHA) or vehicle

23 d adult rat ventricular myocytes (ARVM), the A(1) receptor agonist cyclopentyladenosine (CPA) inhibit

24 Treatment with an A(1) receptor agonist decreases EPSC amplitude and reduc

25 Intrathalamic infusion of A1 receptor agonists directly reduces tremor, whereas ad

26 lts support development of partial adenosine A1-receptor agonists for the treatment of chronic heart

27 The selective low efficacy adenosine A1 receptor agonist, GR190178 (30-1000 microg/kg i.v.),

28 nistration of the highly selective adenosine A1 receptor agonist, GR79236 (3-100 microg/kg) had a dos

29 Therapy with adenosine A1-receptor agonists, however, is limited by undesirable

30 sites was signficantly reduced by adenosine A1 receptor agonists injected through intrathecal cathet

31 N6-Cyclopentyl adenosine (adenosine A1 receptor agonist, Kd = 1 nmol/l) did not affect GLUT1

32 derable literature to suggest that adenosine A1 receptor agonists may have anti-nociceptive effects,

33 The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA) ind

34 hwork cells to the addition of the adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA).

35 rived from the IMHV of untrained chicks, the A(1) receptor agonist N(6)-cyclohexyladenosine (CHA; 10

36 ylxanthine (CPDX; 5 microM and 50 microM) or A(1) receptor agonist, N(6)-cyclopentyladenosine (CPA; 5

37 ystemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine (CHA; 0.3

38 Intrastriatal microinfusion of adenosine A1 receptor agonist N6-cyclohexyladenosine (CHA) and ant

39 Pretreatment with the adenosine A1 receptor agonist N6-cyclohexyladenosine (CHA) or the

40 cholinergic neurons, the selective adenosine A1 receptor agonist N6-cyclohexyladenosine, administered

41 was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine and prevente

42 denosine (CGS-21680; 100 nM), but not by the A1-receptor agonist N6-cyclopentyladenosine (CPA).

43 tudied with the use of a selective adenosine A1 receptor agonist, N6-cyclohexyl-2'-O-methyladenosine

44 In Experiment 1, the selective adenosine A1 receptor agonist, N6-cyclopentyladenosine (CPA), or s

45 cement of [3H]DPCPX binding by the selective A1-receptor agonist, N6-p-sulfophenyladenosine (SPA), yi

46 ts of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV) function a

47 Microinjection of adenosine A1 receptor agonist or an inhibitor of adenylyl cyclase

48 )-adenosine (R-PIA [50 nmol/L], an adenosine A1 receptor agonist), or 4 beta-phorbol 12-myristate 13-

49 Adenosine and the A1 receptor agonist R-phenylisopropyl adenosine (RPIA) r

50 Similarly neither the A1 receptor agonist R-phenylisopropyladenosine (R-PIA),

51 Direct injection of an adenosine A1 receptor agonist replicated the analgesic effect of a

52 tion were reduced in mutants treated with an A(1) receptor agonist, whereas an A(2A) receptor agonist